Radiance Therapeutics is commercializing a novel anti-metabolite therapy designed to reduce scarring and improve outcomes in glaucoma drainage surgery. This therapy addresses the high failure rates associated with traditional surgical methods by enhancing the healing process and maintaining intraocular pressure control.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glaucoma drainage surgery often faces high failure rates due to scarring, which compromises the long-term control of intraocular pressure. Traditional surgical methods can lead to excessive fibrosis, obstructing the drainage pathway and necessitating further interventions.
Solution
Radiance Therapeutics is developing an anti-metabolite therapy designed to mitigate scarring and improve the success rates of glaucoma drainage surgery. Their approach focuses on modulating the healing response post-surgery to prevent excessive scar tissue formation around the drainage implant. By reducing fibrosis, the therapy aims to maintain the patency of the drainage pathway, leading to sustained intraocular pressure control and better long-term outcomes for patients undergoing glaucoma surgery.
Target Audience
The primary target audience includes ophthalmic surgeons specializing in glaucoma and patients undergoing glaucoma drainage surgery who are at risk of scarring-related failure.
Features
- Novel anti-metabolite formulation specifically designed for localized application during glaucoma drainage surgery
- Targeted drug delivery to modulate fibroblast activity and reduce collagen deposition
- Enhanced biocompatibility to minimize inflammatory responses and promote tissue integration
- Potential to improve long-term intraocular pressure control and reduce the need for repeat surgeries